Progress in determining response to treatment in gastrointestinal stromal tumor. Issue 4 (2nd April 2020)

• Record Type: Journal Article
• Authors: Arshad, Junaid; Ahmed, Jibran; Subhawong, Ty; Trent, Jonathan C
• Is Part Of: Expert review of anticancer therapy. Volume 20:Issue 4(2020)
• Page Start: 279
• Page End: 288
• Publication Date: 2020-04-02
• Subjects: Gastrointestinal stromal tumor -- mutational/molecular analysis -- primary/secondary mutation -- ctDNA -- tyrosine kinase inhibitors -- response; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1080/14737140.2020.1745068
• Languages: English
• ISSNs: 1473-7140

Abstract

ABSTRACT: Introduction : Gastrointestinal stromal tumor (GIST) is the most common malignant mesenchymal tumor of the gastrointestinal system. Multiple advances in the management of GIST from the discovery of KIT/PDGRA and other genetic alterations have led to the development of multiple tyrosine kinase inhibitors. Response assessment in GIST is determined with iRECIST (Response Evaluation Criteria in Solid Tumors), PERCIST (PET response criteria in solid tumors), or Choi criteria. Molecular genotyping of the tissue samples is the recent standard for diagnosis, treatment, and response to treatment. Areas covered : In this study, we provide a brief overview of the history of the GIST, molecular sequencing, available treatment options and clinical trials, radiologic response assessment, and the role of ctDNA in response evaluation. Expert opinion : Future GIST management is related to the development of sensitive assays to detect genetic alterations for initial diagnosis, treatment selection, monitoring the response to treatment, resistant mutations, and predicting survival.